RegeneRx Biopharmaceuticals, Inc. RGRX
OTC PK
| 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | 03/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 0.00% | 0.00% | 0.00% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00% | 0.00% | 0.00% | -- | -- |
| Cost of Revenue | -- | -- | -100.00% | -- | -- |
| Gross Profit | 8.78% | 9.56% | 10.34% | -- | -- |
| SG&A Expenses | -0.26% | 5.72% | 16.36% | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.68% | 5.23% | 15.75% | -- | -- |
| Operating Income | 0.71% | -5.53% | -16.72% | -- | -- |
| Income Before Tax | -2.83% | -8.12% | -17.82% | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.83% | -8.12% | -17.82% | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.83% | -8.12% | -17.82% | -- | -- |
| EBIT | 0.71% | -5.53% | -16.72% | -- | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.27% | -4.59% | -11.77% | -- | -- |
| Normalized Basic EPS | 1.99% | -1.20% | -8.03% | -- | -- |
| EPS Diluted | 0.20% | -3.11% | -11.77% | -- | -- |
| Normalized Diluted EPS | 1.99% | -1.20% | -8.03% | -- | -- |
| Average Basic Shares Outstanding | 1.76% | 3.60% | 5.54% | -- | -- |
| Average Diluted Shares Outstanding | 1.76% | 3.60% | 5.54% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |